Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Naveen Rathor"'
Autor:
Jamy Ard, Cecilie Olivia Andersen, Kasper Sommer Matthiessen, Camilla S. Morgen, Naveen Rathor, Deepak Yerragolam, Abd A, Tahrani
Publikováno v:
Obesity Facts, Pp 1-1 (2023)
Introduction: The aim of the study was to compare eligible individuals who were or were not treated with bariatric surgery and describe disease burden, treatment, and healthcare costs over 3 years in individuals who were not. Methods: Adults with obe
Externí odkaz:
https://doaj.org/article/6cf27206dd20460485912d2b4e7197b9
Autor:
Henriette H. Nerild, Andreas Brønden, Ida M. Gether, Pernille H. Hellmann, Mille Baekdal, Matthew P. Gillum, Jens S. Svenningsen, Bolette Hartmann, Naveen Rathor, Hanna Angelene Kudiyanur Muniraju, Jens F. Rehfeld, Jens J. Holst, Tina Vilsbøll, David P. Sonne, Filip K. Knop
Publikováno v:
Nerild, H H, Brønden, A, Gether, I M, Hellmann, P H, Baekdal, M, Gillum, M P, Svenningsen, J S, Hartmann, B, Rathor, N, Kudiyanur Muniraju, H A, Rehfeld, J F, Holst, J J, Vilsbøll, T, Sonne, D P & Knop, F K 2023, ' Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility ', Diabetes, Obesity and Metabolism, vol. 25, no. 6, pp. 1632-1637 . https://doi.org/10.1111/dom.15017
AIM: Liraglutide treatment is associated with gallbladder-related disorders and has been shown to delay postprandial gallbladder refilling. The gut hormones cholecystokinin (CCK), fibroblast growth factor 19 (FGF19) and glucagon-like peptide 2 (GLP-2
Autor:
null Henriette H. Nerild, null Andreas Brønden, null Ida M. Gether, null Pernille H. Hellmann, null Mille Baekdal, null Matthew P. Gillum, null Jens S. Svenningsen, null Bolette Hartmann, null Naveen Rathor, null Hanna Angelene, null Jens F. Rehfeld, null Jens J. Holst, null Tina Vilsbøll, null David P. Sonne, null Filip K. Knop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c62419f3a1b23465ba8695ceb2d78b2d
https://doi.org/10.1111/dom.15017/v2/response1
https://doi.org/10.1111/dom.15017/v2/response1
Publikováno v:
International Journal of Orthopaedics Sciences. 8:110-114
Publikováno v:
Diabetes, obesitymetabolism.
Liraglutide is marketed in Europe as Victoza® (1.2 mg/1.8 mg), indicated for glycaemic control in type 2 diabetes, and Saxenda® (3.0 mg), indicated for weight management in adults with obesity. We performed a post-authorization safety study (PASS)
Autor:
El-Khatib Firas H, Rabab Z. Jafri, Steven Russell, Tina Graungaard, Raj Selagamsetty, Naveen Rathor, Jordan Sherwood, Evelyn Greaux, Magnus Ekelund, Mallory A. Hillard, Edward R. Damiano, Courtney A. Balliro
Publikováno v:
Diabetes Therapy
Introduction We investigated the safety of, and glucose control by, the insulin-only configuration of the iLet® bionic pancreas delivering fast-acting insulin aspart (faster aspart), using the same insulin-dosing algorithm but different time to maxi
Publikováno v:
International Journal of Orthopaedics Sciences. 7:884-886
Autor:
Line Quist Bendtsen, Hanne Haahr, Mette Dahl Bendtsen, Thekla von dem Berge, Naveen Rathor, Torben Biester, Thomas Danne
Publikováno v:
Pediatric Diabetes
Background Fast‐acting insulin aspart (faster aspart) is a novel formulation of insulin aspart (IAsp) ensuring ultrafast absorption and effect. Aim To compare the pharmacokinetics between faster aspart and IAsp, based on free or total IAsp measurem
Autor:
Edward Franek, Alfonso Soto Gonzalez, Naveen Rathor, Ludger Rose, Hak Chul Jang, Elena Favaro, Maiken I.S. Kjærsgaard, Alejandra Oviedo, Giorgio Sesti, Wendy Lane, Peter A. Senior
Publikováno v:
Diabetes Care
OBJECTIVE To evaluate the efficacy and safety of fast-acting insulin aspart (faster aspart) compared with insulin aspart (IAsp), both with insulin degludec with or without metformin, in adults with type 2 diabetes not optimally controlled with a basa